United Therapeutics CEO sells 9,500 shares in $502–$506 trades
United Therapeutics’ CEO, via family trusts, exercised 9,500 options and sold the resulting shares under a pre-arranged Rule 10b5-1 plan.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $117.76 per share on September 14, 2026, receiving 9,500 common shares and then selling those 9,500 shares in multiple open-market trades around $502–$506 per share. The option exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and 442,410 options of this grant remain held by a family trust after the exercise.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.67M approx. pre-tax spread)
Exercise and Sale
12 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($4.79M)
Approx. gross sale proceeds
$4.79M
Approx. exercise cost
$1.12M
Approx. pre-tax spread
$3.67M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F11, F12 | 9,500 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 9,500 | $117.76 | $1.12M |
| Sale | Common Stock F1, F3, F2 | 1,580 | $502.1512 | $793K |
| Sale | Common Stock F1, F4, F2 | 2,358 | $503.4406 | $1.19M |
| Sale | Common Stock F1, F5, F2 | 2,722 | $504.4745 | $1.37M |
| Sale | Common Stock F1, F6, F2 | 2,400 | $505.2538 | $1.21M |
| Sale | Common Stock F1, F7, F2 | 440 | $506.4805 | $223K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F8 | -- | -- | -- |
| holding | Common Stock F9 | -- | -- | -- |
| holding | Common Stock F10 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 442,410 contracts (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (12)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F11. These stock options vested in equal one-third installments on March 15, 2021, 2022 and 2023.
- F12. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $501.86 to $502.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $502.87 to $503.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $503.87 to $504.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $504.88 to $505.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $505.97 to $506.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F9. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
Key Figures
Options exercised: 9,500 options
Exercise price: $117.76 per share
Shares sold: 9,500 shares
+5 more
8 metrics
Options exercised
9,500 options
Stock options exercised into common stock on September 14, 2026
Exercise price
$117.76 per share
Exercise price of stock options converted into 9,500 UTHR shares
Shares sold
9,500 shares
Total UTHR common shares sold in multiple trades on September 14, 2026
Sale prices (examples)
$502.1512–$506.4805 per share
Weighted average prices for sale tranches of UTHR shares on September 14, 2026
Remaining options (this grant)
442,410 options
Stock options held by a family trust after the reported exercise
10b5-1 plan option limit
1,734,410 options
Maximum options to be exercised under the CEO’s 10b5-1 plan
Plan end date
December 31, 2026
Latest date the Rule 10b5-1 plan remains in effect, absent earlier completion
Direct UTHR share holding
40,513 shares
Common stock held directly by the CEO following the reported date
Key Terms
Rule 10b5-1 trading plan, stock options, weighted average price, family trusts, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and sale of the resulting shares of common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average price financial
"The price reported above reflects the weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
investment power financial
"shares investment power and the Reporting Person and immediate family members are beneficiaries"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did UTHR’s CEO report on September 14, 2026?
UTHR’s CEO Martine A. Rothblatt reported exercising 9,500 stock options at $117.76 per share and receiving 9,500 common shares, then selling all 9,500 shares in multiple open-market trades with weighted average prices between about $502 and $506 per share.
Were the September 14, 2026 UTHR insider transactions under a Rule 10b5-1 plan?
Yes. The option exercise and related sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Martine A. Rothblatt on November 7, 2025, as described in the filing footnotes.
How many United Therapeutics (UTHR) options does the CEO still hold from this grant?
After exercising 9,500 options on September 14, 2026, a family trust associated with the CEO continues to hold 442,410 stock options from this grant, according to the reported post-transaction derivative holding.
What are the key dates and limits of the CEO’s UTHR 10b5-1 plan?
The Rule 10b5-1 plan was adopted on November 7, 2025. It continues until the earlier of the exercise of 1,734,410 stock options, all expiring on March 15, 2027, or December 31, 2026, as stated in the footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
